Equity Profile

GRFS

Grifols, S.A.

Health CareBiotechnology$5.2B

Feb28Mon

Pre-Earnings Brief

UpcomingQ3-2021After Close9:00 AM EST

Company Snapshot

Grifols, S.A. is a global healthcare company specializing in biotechnology, particularly in the development of plasma-derived medicines....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and increase sales, which is crucial for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

GRFS Q3-2021 Earnings Preview

Context

Company Snapshot

Grifols, S.A. is a global healthcare company specializing in biotechnology, particularly in the development of plasma-derived medicines. With a market cap of $6 billion, Grifols plays a significant role in the healthcare sector, addressing critical medical needs through innovative therapies.

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

14%

Avg EPS Surprise

-3.86%

Avg Stock Reaction

+1.41%

Last Quarter Recap

In the last quarter, Grifols reported an EPS of $0.24, which was below the expected $0.27, leading to a slight stock increase of 1.76% the following day. The company has faced challenges in meeting earnings expectations, which could influence investor sentiment.

Management Promises & Guidance

Focus on improving operational efficiency.
Commitment to expanding plasma collection capabilities.
Plans to enhance product portfolio with new therapies.

Expectations

Wall Street Expectations

Overall, analysts are cautious about Grifols' upcoming earnings due to recent misses and lack of guidance. Investors are looking for signs of recovery in profitability and growth.

Bull Case

If Grifols can demonstrate strong plasma collection growth and improved EPS, it could signal a turnaround, boosting investor confidence.

Bear Case

Continued earnings misses and weak revenue growth could lead to further declines in stock price, as investors may lose faith in the company's recovery strategy.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current plasma collection volume and how does it compare to previous quarters?

This metric is crucial as it directly affects the company's ability to produce and sell plasma-derived products, impacting future revenue.

Will the EPS meet or exceed expectations this quarter?

Given the recent earnings misses, a positive EPS could restore investor confidence and stabilize the stock price.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Grifols to rebound in plasma collection, which could lead to stronger-than-expected revenue growth this quarter.

Supporting Evidence

The recent focus on expanding plasma collection capabilities suggests a strategic shift that may not be fully reflected in current estimates.

Options pricing indicates a significant move, suggesting that traders expect a substantial change in sentiment post-earnings.

Key Risk

If plasma collection volume exceeds expectations, it could invalidate the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Grifols' ability to recover from previous earnings misses and improve operational performance.

Bull Confirmed If

A plasma collection volume increase of over 15% year-over-year would confirm the bull case.

Bear Confirmed If

An EPS of less than $0.20 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±30.22%

Historical Avg

±1.5%

Pricing rich

The options market is pricing in a significant potential movement in Grifols' stock, indicating heightened uncertainty ahead of the earnings report.

Options are pricing ±6.1% while GRFS has averaged ±1.5% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

35.6%

Calls (22K)P/C Ratio: 0.33Puts (600)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Grifols beats expectations, history suggests the stock could rise by around 0.10%, confirming a positive outlook.

In-Line / Cautious

A cautious inline report could lead to muted stock movement, as investors await clearer signs of recovery.

Miss

If the company misses again, history suggests a potential decline of about 1.35%, raising concerns about its growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on plasma collection growth and operational improvements.
2Any commentary on new product launches or pipeline developments.
3Management's outlook on revenue growth for the next quarter.
4Details on cost management strategies and efficiency improvements.
5Insights into market demand for plasma-derived therapies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Feb25

DHILReported

Diamond Hill Investment Group, Inc.

RecapView

Feb28

JLLReported

Company Snapshot

Grifols, S.A. is a global healthcare company specializing in biotechnology, particularly in the development of plasma-derived medicines....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and increase sales, which is crucial for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

GRFS Q3-2021 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

14%

Avg EPS Surprise

-3.86%

Avg Stock Reaction

+1.41%

Last Quarter Recap

Management Promises & Guidance

Focus on improving operational efficiency.
Commitment to expanding plasma collection capabilities.
Plans to enhance product portfolio with new therapies.

Expectations

Wall Street Expectations

Overall, analysts are cautious about Grifols' upcoming earnings due to recent misses and lack of guidance. Investors are looking for signs of recovery in profitability and growth.

Bull Case

If Grifols can demonstrate strong plasma collection growth and improved EPS, it could signal a turnaround, boosting investor confidence.

Bear Case

Continued earnings misses and weak revenue growth could lead to further declines in stock price, as investors may lose faith in the company's recovery strategy.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current plasma collection volume and how does it compare to previous quarters?

This metric is crucial as it directly affects the company's ability to produce and sell plasma-derived products, impacting future revenue.

Will the EPS meet or exceed expectations this quarter?

Given the recent earnings misses, a positive EPS could restore investor confidence and stabilize the stock price.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Grifols to rebound in plasma collection, which could lead to stronger-than-expected revenue growth this quarter.

Supporting Evidence

The recent focus on expanding plasma collection capabilities suggests a strategic shift that may not be fully reflected in current estimates.

Options pricing indicates a significant move, suggesting that traders expect a substantial change in sentiment post-earnings.

Key Risk

If plasma collection volume exceeds expectations, it could invalidate the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Grifols' ability to recover from previous earnings misses and improve operational performance.

Bull Confirmed If

A plasma collection volume increase of over 15% year-over-year would confirm the bull case.

Bear Confirmed If

An EPS of less than $0.20 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±30.22%

Historical Avg

±1.5%

Pricing rich

The options market is pricing in a significant potential movement in Grifols' stock, indicating heightened uncertainty ahead of the earnings report.

Options are pricing ±6.1% while GRFS has averaged ±1.5% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

35.6%

Calls (22K)P/C Ratio: 0.33Puts (600)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Grifols beats expectations, history suggests the stock could rise by around 0.10%, confirming a positive outlook.

In-Line / Cautious

A cautious inline report could lead to muted stock movement, as investors await clearer signs of recovery.

Miss

If the company misses again, history suggests a potential decline of about 1.35%, raising concerns about its growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on plasma collection growth and operational improvements.
2Any commentary on new product launches or pipeline developments.
3Management's outlook on revenue growth for the next quarter.
4Details on cost management strategies and efficiency improvements.
5Insights into market demand for plasma-derived therapies.